RxDoctor Payments Data

Kenan Si, MD

Family Medicine · Sacramento, CANPI 1124144266

Payments from drug & device makers

$585in general payments, 2019–2025

Across 18 payments — averaging $32.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$264
  • AbbVie$156
  • Boehringer Ingelheim$125
  • Biotronik Inc.$27
  • Merck$13

What the payments were for

  • Food & beverage$585100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$585 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$283,829
Medicare patients
196
Services billed
3,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$132,068
ProliaDenosumab71$108,632
JardianceEmpagliflozin85$105,988
JanuviaSitagliptin Phosphate69$94,679
VascepaIcosapent Ethyl121$57,545
Icosapent Ethyl224$45,593
LinzessLinaclotide22$31,827
TradjentaLinagliptin22$30,033
FarxigaDapagliflozin Propanediol14$19,594
Rasagiline Mesylate18$8,255
Tresiba Flextouch U-100Insulin Degludec15$7,858
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,381
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$5,372
Azelastine Hcl206$5,223
Tacrolimus24$4,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$125$136,021107 claims
MerckJanuvia$13$94,67969 claims
AbbVieLinzess$156$31,82722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →